Serina Therapeutics, Inc. (NYSEAMERICAN:SER – Get Free Report) Director Karen Wilson acquired 10,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were bought at an average cost of $1.77 per share, with a total value of $17,700.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at $17,700. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Serina Therapeutics Stock Performance
NYSEAMERICAN:SER opened at $1.92 on Wednesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.18 and a quick ratio of 4.18. The stock has a market cap of $28.80 million, a PE ratio of -0.96 and a beta of 1.15. The business’s 50 day moving average is $1.96. Serina Therapeutics, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $7.92.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.
Serina Therapeutics Company Profile
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Featured Stories
- Five stocks we like better than Serina Therapeutics
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
